Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Di Nicolantonio, Federica; Martini, Miriam; Molinari, Francesca; Sartore‐Bianchi, Andrea; Arena, Sabrina; Saletti, Piercarlo; De Dosso, Sara; Mazzucchelli, Luca; Frattini, Milo; Siena, Salvatore; Bardelli, Alberto

doi:10.1200/jco.2008.18.0786

Public

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Published in Journal of Clinical Oncology • Nov 11, 2008

Authors:

Federica Di Nicolantonio

Miriam Martini

Francesca Molinari

Abstract

PURPOSE Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40% patients who are not responsive. The serine-threonine kinase BRAF is the principal effector of KRAS. We hypothesized that, in KRAS ...

Subject

Panitumumab

Cetuximab

KRAS

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!